π’ ππππ ππ: $ImmunityBio(IBRX.US) ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 β¦
π’ ππππ ππ: $ImmunityBio(IBRX.US) ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.